LogicBio Therapeutics (OTCMKTS:LOGC) Issues Earnings Results

LogicBio Therapeutics (OTCMKTS:LOGC) posted its quarterly earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10), Zacks reports.

LogicBio Therapeutics Trading Up 0.5%

LOGC traded up $0.05 on Thursday, reaching $10.55. 127,031 shares of the company’s stock were exchanged, compared to its average volume of 139,958. The company’s 50 day moving average is $9.36 and its 200-day moving average is $8.66. The company has a market cap of $482.45 million, a price-to-earnings ratio of -9.68 and a beta of 2.02. LogicBio Therapeutics has a twelve month low of $7.05 and a twelve month high of $10.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.15 and a current ratio of 1.67.

Institutional Investors Weigh In On LogicBio Therapeutics

A hedge fund recently raised its stake in LogicBio Therapeutics stock. Goldman Sachs Group Inc. lifted its holdings in LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) by 284.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 526,673 shares of the company’s stock after acquiring an additional 389,843 shares during the period. Goldman Sachs Group Inc. owned approximately 2.00% of LogicBio Therapeutics worth $3,676,000 as of its most recent SEC filing. Institutional investors own 46.05% of the company’s stock.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.